We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

58 hedge funds and large institutions have $272M invested in Audentes Therapeutics, Inc in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

2% more funds holding

Funds holding: 57 → 58 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less capital invested

Capital invested by funds: $283M → $272M (-$10.8M)

Holders
58
Holders Change
+1
Holders Change %
+1.75%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
19
Reduced
15
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13.9M
2
CC
Casdin Capital
New York
+$4.21M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.76M
4
Victory Capital Management
Victory Capital Management
Texas
+$728K
5
SIM
Spark Investment Management
New York
+$448K

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$748K
2
CAM
Cormorant Asset Management
Massachusetts
-$404K
3
RI
RTW Investments
New York
-$365K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$307K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$294K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$81.8M – – –
VVM
2
Versant Venture Management
California
$30.8M – – –
DM
3
Deerfield Management
New York
$23.9M – – –
BlackRock
4
BlackRock
New York
$15.1M +$13.9M +856,397 +2,916%
RG
5
Redmile Group
California
$14M -$192K -11,900 -1%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$10.4M +$2.76M +170,511 +39%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$9.55M -$294K -18,200 -3%
RCM
8
RA Capital Management
Massachusetts
$9.07M – – –
RSCM
9
Rock Springs Capital Management
Maryland
$8.52M +$243K +15,000 +3%
AllianceBernstein
10
AllianceBernstein
Tennessee
$8.3M -$748K -46,221 -9%
VMI
11
VHCP Management II
New York
$7.82M – – –
CAM
12
Cormorant Asset Management
Massachusetts
$7.24M -$404K -25,000 -6%
Franklin Resources
13
Franklin Resources
California
$6.25M – – –
Fidelity Investments
14
Fidelity Investments
Massachusetts
$5.64M -$307K -19,000 -5%
Jennison Associates
15
Jennison Associates
New York
$5.11M – – –
Vanguard Group
16
Vanguard Group
Pennsylvania
$5.02M +$360K +22,283 +8%
CC
17
Casdin Capital
New York
$4.43M +$4.21M +260,000 New
EAM
18
Eventide Asset Management
Massachusetts
$3.83M – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$1.87M -$225K -13,915 -11%
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
$1.71M +$3.93K +243 +0.2%
Millennium Management
21
Millennium Management
New York
$1.47M -$21.3K -1,318 -2%
Victory Capital Management
22
Victory Capital Management
Texas
$1.26M +$728K +45,024 +156%
State Street
23
State Street
Massachusetts
$1.14M +$60.7K +3,752 +6%
FCMI
24
Foresite Capital Management III
California
$1.13M – – –
Northern Trust
25
Northern Trust
Illinois
$929K +$101K +6,255 +13%
1
2 3

BOLD Hedge Fund Activity: Q1 2017 in Review

58 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2017, worth a combined $272M — down 3.8% from $283M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BOLD positions and 2 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $13.9M. The largest seller was AllianceBernstein, cutting an estimated $748K.

  • 58 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $272M of Audentes Therapeutics, Inc stock for Q1 2017, down 3.8% quarter-over-quarter.
  • 9 funds opened new Audentes Therapeutics, Inc positions in Q1 2017 and 2 closed out, a net change of +7 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q1 2017 was BlackRock, an estimated $13.9M added.
  • The largest Audentes Therapeutics, Inc seller in Q1 2017 was AllianceBernstein, an estimated $748K sold.

Based on aggregated 13F filings for Q1 2017.